Abstract—The COVID-19 pandemic, stemming from a novel coronavirus outbreak in 2019, has resulted in significant loss of life and widespread disruption to societal and economic functions globally. Thymoquinone (TQ), a natural compound sourced from Nigella sativa, has garnered attention for its potential in mitigating and treating COVID-19. This paper provides an overview of inhaled nano-formulations designed for the localized pulmonary delivery of TQ. These formulations hold promise for enhancing the efficacy of TQ in combating respiratory infections, including COVID-19. However, challenges persist in translating TQ-loaded inhaled nano-formulations into clinical applications. Factors such as stability, bioavailability, and safety must be carefully addressed to ensure the feasibility and effectiveness of these formulations in clinical settings. This review highlights the current advancements and hurdles in utilizing TQ-loaded inhaled nano-formulations for combating COVID-19 and underscores the need for further research and development in this promising area.

Keywords—COVID-19, nano-drug, delivery system, thymoquinone, SARS-CoV-2

Cite: Chengwei Jiang, "The Thymoquinone Inhalable Nano-drug Delivery System with COVID-19 Therapeutic Potential," International Journal of Pharma Medicine and Biological Sciences, Vol. 13, No. 3, pp. 80-85, 2024.

Copyright © 2024 by the authors. This is an open access article distributed under the Creative Commons Attribution License (CC BY-NC-ND 4.0), which permits use, distribution and reproduction in any medium, provided that the article is properly cited, the use is non-commercial and no modifications or adaptations are made.